Shin Poong and LFB set up joint venture to manufacture biotech products

11 January 2013

South Korean drugmaker Shin Poong Pharmaceutical (KOSPI: 019170) and France’s Laboratoire francais du Fractionnement et des Biotechnologies (LFB) have signed a term sheet for the establishment of a joint venture for the production and supply of biotechnology medicinal products.

Both parties will aim to sign a definitive agreement during the first half of 2013 and set up a purification and fill and finish manufacturing facility in South Korea. The share ratio will be 55% for Shin Poong and 45% for LFB and the JV will be governed by joint board members and management committee.

First products to be ATryn and FVIIa

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK